Hinge Health (HNGE) Director M.I. Sells $21M of Stock
Mecklenburg Gabriel M.I., a director at Hinge Health, sold 200,000 shares on October 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mecklenburg Gabriel M.I., Director at Hinge Health, Inc. ($HNGE), sold 200,000 shares at an average price of $103.13, worth about $20.63 million, on October 12, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $HNGE is down 5.4% to date (from the $104.82 close on Oct 12, 2026).
HNGE
Hinge Health, Inc.
Key Points
- Mecklenburg Gabriel M.I. sold 200,000 shares of Hinge Health at an average price of $103.13, totaling about $20.6 million.
- The stock recently traded around $99.47, which is about 11.3% below the average price target of $112.13 set by analysts.
- Hinge Health has a strong revenue growth rate of 53.0% year-over-year and a net margin of 15.1%.
Get $HNGE trade alerts by text
We text you when insiders, Congress or big funds trade $HNGE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Hinge Health, Inc. alert may contain errors. Disclosures
Mecklenburg Gabriel M.I., a director at Hinge Health, Inc. (NYSE: HNGE), sold 200,000 shares on October 12, 2026, for a total value of about $20.63 million. This transaction was part of a planned sale, as indicated by the filing.
Inside Mecklenburg Gabriel M.I.'s Trade
Mecklenburg Gabriel M.I. sold 200,000 shares at an average price of $103.13.
Other Institutional Activity in Hinge Health
Several other institutional investors have also been active with Hinge Health. Blackrock Inc. holds 3,570,131 shares worth about $354 million after increasing its stake by 2,662,624 shares. Vanguard Portfolio Management LLC owns 2,146,032 shares valued at roughly $212.8 million, having added 735,375 shares recently. In contrast, 11.2 Capital Management, LLC reduced its holdings by 1,239,923 shares, ending with 2,464,657 shares worth about $244.4 million.
Hinge Health, Inc. Stock Down 5.3%
The stock recently traded around $99.47 as of October 16, 2026, which is above its 50-day moving average by about 7.4% and its 200-day moving average by about 57.2%. However, it remains about 11.3% below the average analyst price target of $112.13.
Recent Earnings
Hinge Health reported trailing twelve-month revenue of $720.1 million, with an earnings per share (EPS) of $3.03. The company has shown strong revenue growth of 53.0% year-over-year and a net margin of 15.1%. The next earnings report is scheduled for November 2, 2026.
Insider Buying and Selling at Hinge Health, Inc.
Earlier this year, LLC Insight Holdings Group has been active in trading Hinge Health shares. On June 29, 2026, they sold 1,466,667 shares under a planned sale for about $121.5 million at an average price of $82.84. This followed multiple purchases in June, where they added a total of 2,000,000 shares.
Analysts Set New Price Targets
On October 12, 2026, Barclays maintained an Overweight rating on Hinge Health with a price target of $110. Earlier, Truist Securities also maintained a Buy rating with a price target of $112. The consensus recommendation among analysts is a Buy, with a mean price target of $112.13.
About Hinge Health
Hinge Health, Inc. focuses on improving musculoskeletal care through technology. The company provides AI-powered solutions and a wearable device for pain management and rehabilitation. It primarily serves self-insured employers, helping to reduce costs associated with musculoskeletal injuries.
Bottom Line
Investors will be watching Hinge Health closely, especially with the upcoming earnings report on November 2, 2026. Keep an eye on any further insider trading activity as the company continues to navigate the healthcare landscape.
Related Filing Alerts
Source: Mecklenburg Gabriel M.I.'s Form 4 filing on $HNGE (Oct 12, 2026). Find the original filing: HNGE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts